Intranasal COVID-19 vaccine shown to be effective in animal models
A nasal spray of the COVID-19 Vaccine Oxford/AstraZeneca was found to protect hamsters and monkeys against SARS-CoV-2 in an NIH study.
List view / Grid view
A nasal spray of the COVID-19 Vaccine Oxford/AstraZeneca was found to protect hamsters and monkeys against SARS-CoV-2 in an NIH study.
Hear about the latest Drug Target Review updates from Deputy Editor Victoria Rees who discusses our new report on AI & Informatics, the Cell & Gene Therapy Advancements online summit and much more!
Scientists used artificial intelligence to identify 17 existing drugs that could kill SARS-CoV-2 in cells, including a dietary supplement.
Researchers have revealed a novel mechanism for platelet activation, suggesting a potential target for antithrombotic therapy.
A supercomputing method has revealed details of glycan “gates” on the SARS-CoV-2 Spike protein that open to allow virus entry and infection.
CureVac and GSK's second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response in a pre-clinical study.
A new study has identified a vital enzyme, known as APOBEC3A, that could lead to new treatments against cancers and viral infections.
Fenofibrate and its active form, fenofibric acid, have been shown to significantly reduce COVID-19 infection in human cells.
Researchers have been using artificial intelligence to study how the microbiome interacts with the human system to improve vaccine response.
In this article, Dr Jon Volmer and Dr Jon Lenn discuss a new approach to formulation models to test drug delivery based on reconstituted nasal epithelium.
NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
Scientists from the University of Chicago discovered that the drug masitinib inhibits the replication of SARS-CoV-2 in mice.
Listen to this podcast to discover how SARS-CoV-2 variants are sequenced and why PCR assays could provide an alternative for resource-constrained places.
A new “atlas” has been created in the US that charts how 152 different antibodies attack the SARS-CoV-2 Spike protein.
A new computer algorithm has identified highly conserved sequences in viral proteins that could make the best drug targets for COVID-19.